Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma reported Q2 2026 results with continued enrollment in its ASCEND Phase 1/2 trial for CR-001, a PD-1 x VEGF bispecific antibody. The company completed a $143.7 million public offering extending cash runway to H2 2028 and announced multiple clinical data readouts expected beginning Q1 2027. R&D expenses increased to $19.4 million due to expanded clinical activities, while the company maintains strategic partnerships with Kelun-Biotech for development in Greater China.